Cochlear Implants for Hearing Loss
(ACE Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests the safety and effectiveness of cochlear implants for adults with bilateral sensorineural hearing loss. The researchers aim to determine if individuals who do not meet the usual qualifications for cochlear implants could still benefit from them. Participants will receive a Cochlear™ Nucleus® implant and undergo speech perception tests at several visits. Suitable candidates have significant hearing loss in both ears but do not qualify for traditional cochlear implants.
As an unphased trial, this study offers a unique opportunity for patients to explore new possibilities for hearing improvement.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinator or your doctor.
What prior data suggests that cochlear implantation is safe for adults with bilateral sensorineural hearing loss?
Research has shown that cochlear implants, including the Cochlear™ Nucleus® System, are generally safe. In one study involving children with these implants, 60 issues occurred in 227 ears, with 14 classified as major. This indicates that about 26% experienced some problems, though serious issues were less frequent. The Cochlear Nucleus system is FDA-approved for specific types of hearing loss, indicating it has been tested and found safe for those cases. These findings suggest that cochlear implants are usually well-tolerated, although, like any medical procedure, some risks exist.12345
Why are researchers excited about this trial?
Unlike other treatments for hearing loss, which often rely on hearing aids to amplify sound, the Cochlear™ Nucleus® System directly stimulates the auditory nerve. This approach bypasses damaged parts of the ear entirely, offering a unique solution for individuals with severe to profound hearing loss who don't benefit from hearing aids. Researchers are excited because this system can provide a more natural hearing experience, potentially improving speech understanding and quality of life for users.
What evidence suggests that cochlear implantation is effective for hearing loss?
Research shows that cochlear implants, such as the Cochlear™ Nucleus® System, work well for individuals with moderate to severe hearing loss. Studies have found that patients understand speech much better after receiving the implant. On average, within three months, users notice significant improvement in recognizing speech compared to before the implant. These benefits persist over time, making the cochlear implant a dependable option. The implant is also considered safe, with studies confirming its successful use across various age groups.16789
Are You a Good Fit for This Trial?
This trial is for adults with bilateral sensorineural hearing loss who don't currently qualify for cochlear implants under FDA guidelines. Participants will be assessed over seven visits after receiving the implant.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Cochlear Implantation
Participants will be implanted with a commercially approved Cochlear™ Nucleus® implant
Post-implantation Assessment
Participants complete speech perception assessments and questionnaires over the course of seven visits
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Cochlear Implantation
Cochlear Implantation is already approved in United States, European Union for the following indications:
- Severe to profound sensorineural hearing loss in both ears
- Moderate to profound sensorineural hearing loss in both ears with limited benefit from amplification
- Single-sided deafness/unilateral hearing loss (SSD/UHL)
- Severe to profound sensorineural hearing loss in both ears
- Moderate to profound sensorineural hearing loss in both ears with limited benefit from amplification
Find a Clinic Near You
Who Is Running the Clinical Trial?
Cochlear
Lead Sponsor
Dig Howitt
Cochlear
Chief Executive Officer since 2018
BE (Hons), MBA
Michael del Prado
Cochlear
Chief Medical Officer since 2022
MD, MSc, FRACP, FAAHMS, FAICD
Althea Anagnostopoulos Harrington
Collaborator
MV Clinical Research, LLC
Collaborator
LWB Consulting
Collaborator
NAMSA
Collaborator